By Jordan A. Rothacker

Scientific research is a major economic driver, supporting industries that range from agriculture and health care to data and advanced manufacturing. In Georgia, universities play a central role in that ecosystem, not only producing research but increasingly helping bring it to market.

The state ranks second nationally in the share of university research funded by industry, according to the Georgia Department of Economic Development. That positioning reflects a broader strength: Georgia has built a system that connects academic discovery with commercial application.

At the center of that system is the Georgia Research Alliance (GRA), a nonprofit that has worked since 1990 to link universities, businesses, and investors. In partnership with the University System of Georgia and state economic leaders, GRA helps move research out of the lab and into the marketplace.

The scale of that impact is significant. Since its founding, GRA has invested $728 million in state funds, helping attract more than $16 billion in research grants, venture capital, and related funding. According to its 2025 impact report, one in four research dollars received by Georgia universities supports a GRA-affiliated scholar.

Recent projects backed by GRA include agricultural technology aimed at improving crop yields and health innovations focused on early autism detection, examples of how academic research can translate into commercial and clinical applications.

Federal funding remains a major pillar of university research. In 2025, Georgia ranked eighth nationally in overall university R&D spending, up from 12th just a few years earlier.

Individual institutions are also gaining ground. Georgia Tech ranks second nationally in federally sponsored research expenditures, according to the National Science Foundation. The University of Georgia reported a record $654 million in research spending in 2025, supported by agencies that include the Department of Defense, NASA, and the Department of Energy.

UGA has also emerged as a leader in commercialization. AUTM, an organization that tracks technology transfer, ranked the university first in the nation in 2024 for the number of products brought to market based on university research. The university estimates its total economic impact at $9.2 billion.

That pipeline from research to commercialization is visible at the lab level.

At UGA’s Center for Molecular Medicine, researchers move between academic work and applied innovation. Among them is Dr. Nadja Zeltner, who recently launched Neela Cell Therapeutics to advance research into genipin, a compound derived from the gardenia plant.

Zeltner’s work focuses on potential treatments for conditions affecting the peripheral nervous system. While the research is still in early stages, she said moving into a commercial structure can accelerate development.

“To help patients is the whole reason why I am a scientist,” she said. “If you want to move something forward, an industry setting is often faster.”

She credited UGA’s Innovation Gateway with helping guide the transition from research to startup, particularly in navigating early-stage commercialization.

GRA support has also played a role. Zeltner received a Phase 1 grant that helped launch initial work and position the company for additional funding.

Across Georgia, that model is becoming more common. Researchers are not only producing discoveries but increasingly participating in the process of bringing them to market.

That shift helps explain the state’s standing in research and development. Strong funding, institutional support, and a growing culture of entrepreneurship are reinforcing each other.

The result is an R&D ecosystem where academic research does not end in publication, but continues into application, investment, and, in some cases, new companies.